Carsten Brunn is the President and Chief Executive Officer of Cartesian Therapeutics, a clinical-stage biotechnology company focused on developing cell.
Carsten Brunn is the President and Chief Executive Officer of Cartesian Therapeutics, a clinical-stage biotechnology company focused on developing cell therapy for autoimmune diseases. The company is advancing its lead asset, Descartes-08, through Phase 3 clinical development for generalized myasthenia gravis, and also has Descartes-15 in Phase 1 for multiple myeloma. Cartesian Therapeutics reported approximately $120.4 million in cash, cash equivalents, and restricted cash as of March 31, 2026.
Full founder directory · Investor directory · Company funding database · Fundraising library